WuXi Biologics sees quick resolution to U.S. action 

WuXi Biologics CEO Chris Chen doesn’t expect his company’s surprise addition to a U.S. Commerce watch list to last more than a couple of months and, for that matter, to affect the CRO’s operations at all. Investors aren’t so sure, but that sentiment could have less to do with WuXi Biologics than geopolitics.

By Friday, shares of WuXi Biologics Inc. (HKEX:2269) had yet to recover from a 30% tumble on Tuesday after Commerce added two of the company’s subsidiaries to a federal watch list known as the “unverified list,” or UVL, after the agency was unable to inspect the units due to the COVID-19 pandemic. WuXi Biologics’ stock finished the week at HK$56.70 for a four-day loss in valuation of nearly HK$100 billion ($13 billion). ...